Virometix AG has secured a $15 million financing round from its existing shareholders, marking a significant milestone for the Swiss biotechnology company as it accelerates the clinical and developmental progress of its lead synthetic vaccine candidate, V-212. The company, based in Schlieren and focused on next-generation fully synthetic vaccines, confirmed the raise as V-212 continues through its Phase I clinical evaluation.
The new capital will allow Virometix to advance the ongoing Phase I study of V-212, with topline data targeted for early 2026. In addition, the company plans to prepare a Phase Ib combination study that will evaluate the vaccine alongside an approved pneumococcal conjugate vaccine. Funding will also support completion of OPK assay validation to strengthen future immunogenicity and functional data analyses.
Beyond the V-212 program, Virometix intends to enhance its Synthetic Virus-Like Particle technology platform, a core component of its approach to developing fully synthetic, self-adjuvanted vaccine candidates. The company will further apply these enhancements to progress additional serotype-independent pneumococcal vaccine programs toward preclinical development.
The financing reflects strong ongoing support from the company’s investor base as Virometix works to establish novel synthetic vaccine modalities capable of scalable manufacturing and broad protection across pneumococcal strains.
KEY QUOTES
“This financing demonstrates the continued confidence and commitment of our investors to Virometix’s mission and platform. Our fully synthetic SVLP technology enables the design of broad-spectrum, self-adjuvanted vaccines with highly scalable manufacturing. With V-212 in clinical development, we are well positioned to deliver a truly next-generation approach to pneumococcal prevention.”
Anna Sumeray, Chief Executive Officer, Virometix
